Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.

导出 LinkOut

翻译打印收藏纠错

作者： Christina Leah B,Kline ^[1] ; Angelique,Schiccitano ^[1] ; Junjia,Zhu ^[2] ; Cheryl,Beachler ^[1] ; Hassan,Sheikh ^[1] ; Harold A,Harvey ^[1] ; Heath B,Mackley ^[3] ; Kevin,McKenna ^[4] ; Kevin,Staveley-O'Carroll ^[4] ; Lisa,Poritz ^[4] ; Evangelos,Messaris ^[4] ; David,Stewart ^[4] ; Jeffrey,Sivik ^[5] ; Wafik S,El-Deiry ^[6]

作者单位： Hematology/Oncology Division, Department of Medicine, Penn State College of Medicine, Hershey, PA. ^[1] Department of Public Health Sciences, Penn State College of Medicine, Hershey, PA. ^[2] Hematology/Oncology Division, Department of Medicine, Penn State College of Medicine, Hershey, PA; Division of Radiation Oncology, Department of Radiology, Penn State College of Medicine, Hershey, PA. ^[3] Department of Surgery, Penn State College of Medicine, Hershey, PA. ^[4] Department of Pharmacology, Penn State College of Medicine, Hershey, PA. ^[5] Hematology/Oncology Division, Department of Medicine, Penn State College of Medicine, Hershey, PA. Electronic address: weldeiry@hmc.psu.edu. ^[6]

关键词 5-FU Chemotherapy FOLFOX OnDose Personalized cancer therapy